Identification of Potential Biomarkers for Pain

Rowan University

Status: Unknown

Conditions: Fibromyalgia

Study type: Observational

Funder types: Other

Identifiers

NCT03495245

Pro2017001740

Details and patient eligibility

About

The study investigates the potential of using serum biomarkers to assess pain in fibromyalgia patients.

Full description

At the heart of the opioid epidemic is the lack of an objective measure of pain, which will help evaluate the validity of the patients' perception that the current dosage of opioid is sufficient of insufficient to alleviate pain. This study will test the quantifiable proteins such as S100B and BDNF will serve as objective measures (biomarkers) of pain.

Fibromyalgia patients will be recruited into two groups-- one that uses opioids and the other that does not. Blood will be collected every 6 months for two years. The serum will be used to assay for levels of S100B and BDNF, The pressure-pain threshold (PPT) data, as part of standard of care, will also be collected. Correlation will the be assessed.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with Fibromyalgia

Exclusion criteria

• Evidence of a history of substance abuse, neurological or oncologic disease, ischemic heart disease, kidney or hepatic insufficiency.

Trial design

200 participants in 2 patient groups

Opioid Usage

Description:

Patients that are currently diagnosed with fibromyalgia and taking opioids.

No Opioid Usage

Description:

Patients that are currently diagnosed with fibromyalgia and are not taking opioids.